FDA approved asthma therapeutic agent impacts amyloid {beta} in the brain in a transgenic model of Alzheimer’s disease [Molecular Bases of Disease]

December 2nd, 2014 by Hori, Y., Takeda, S., Cho, H., Wegmann, S., Shoup, T. M., Takahashi, K., Irimia, D., Elmaleh, D. R., Hyman, B. T., Hudry, E.

Interfering with the assembly of Amyloid β (Aβ) peptides from monomer to oligomeric species and fibrils, or promoting their clearance from brain, are targets of anti-Aβ directed therapies in Alzheimer′s disease (AD). Here, we demonstrate that Cromolyn Sodium (disodium cromoglycate), an FDA-approved drug already in use for the treatment of asthma, efficiently inhibits the aggregation of Aβ monomers into higher order oligomers and fibrils in vitro, without affecting Aβ production. In vivo, the levels of soluble Aβ are decreased by over 50% after only 1 week of daily intraperitoneal administered Cromolyn Sodium. Additional in vivo microdialysis studies also show that this compound decreases the half-life of soluble Aβ in the brain. These data suggest a clear effect of a peripherally administered, FDA approved medication on Aβ economy, supporting further investigation of the potential long term efficacy of Cromolyn Sodium in AD.
  • Posted in Journal of Biological Chemistry, Publications
  • Comments Off on FDA approved asthma therapeutic agent impacts amyloid {beta} in the brain in a transgenic model of Alzheimer’s disease [Molecular Bases of Disease]